Evidence map›Paper›PMID 39381136›Full record

ArticleAntibody therapeutics2024

The process using a synthetic library that generates multiple diverse human single domain antibodies.

Mark A Tornetta, Brian P Whitaker, Olivia M Cantwell, Eileen D Pisors, Lu Han, Maria P MacWilliams, Hao Jiang, Fulai Zhou, Mark L Chiu

Abstract read
In one paragraph

Article in Antibody therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mark A TornettaBiologics Discovery Department, Tavotek Biotherapeutics, 727 Norristown Road, Spring house Innovation Park, Building 3, Suite 101, Lower Gywnedd, PA 19002, United States.ORCID https://orcid.org/0009-0002-5997-0426
Brian P WhitakerBiologics Discovery Department, Tavotek Biotherapeutics, 727 Norristown Road, Spring house Innovation Park, Building 3, Suite 101, Lower Gywnedd, PA 19002, United States.
Olivia M CantwellBiologics Discovery Department, Tavotek Biotherapeutics, 727 Norristown Road, Spring house Innovation Park, Building 3, Suite 101, Lower Gywnedd, PA 19002, United States.
Eileen D PisorsBiologics Discovery Department, Tavotek Biotherapeutics, 727 Norristown Road, Spring house Innovation Park, Building 3, Suite 101, Lower Gywnedd, PA 19002, United States.
Lu HanBiologics Discovery Department, Tavotek Biotherapeutics, Building C2, Suzhou Biomedical Industrial Park, Suzhou, Jiang Su 215000, China.
Maria P MacWilliamsBiologics Discovery Department, Tavotek Biotherapeutics, 727 Norristown Road, Spring house Innovation Park, Building 3, Suite 101, Lower Gywnedd, PA 19002, United States.
Hao JiangBiologics Discovery Department, Tavotek Biotherapeutics, Building C2, Suzhou Biomedical Industrial Park, Suzhou, Jiang Su 215000, China.
Fulai ZhouBiologics Discovery Department, Tavotek Biotherapeutics, Building C2, Suzhou Biomedical Industrial Park, Suzhou, Jiang Su 215000, China.
Mark L ChiuBiologics Discovery Department, Tavotek Biotherapeutics, 727 Norristown Road, Spring house Innovation Park, Building 3, Suite 101, Lower Gywnedd, PA 19002, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Single domain antibodies (sdAbs) possess unique characteristics that make them highly effective for developing complex therapeutics. Methods: Our process uses a fully synthetic phage display library to generate single domain antibodies that can bind to disease relevant antigen conformations. A human IGHV3 family scaffold makes up the phage display libraries, and these VHO libraries are applied to diverse phage biopannings against target antigens. After NGS processing, unique VHOs undergo automated cloning into expression constructs followed by transfections and purifications. Binding assays were used to determine VHO binding behaviors to the target proteins. Additional VHO interactions are measured against endogenous targets on cells by way of flow cytometry, cell internalization, and activation assays. Results: We show that a fully synthetic phage display library can generate VHOs that bind to disease relevant antigen conformations. The diverse biopanning methods and processing of next-generation sequencing generated many VHO paratopes. These different VHO sequences can be expressed as Fc fusion proteins. Various screening assays resulted in VHOs representing different epitopes or activities. During the hit evaluation, we demonstrate how screening can identify distinct VHO activities that have been used to generate differentiated drug molecules in various bispecific and multispecific antibody formats. Conclusion: We demonstrate how screening can identify distinct VHO activities that have been used to generate differentiated drug molecules in various bispecific and multispecific antibody formats.

Indexed as

binningbiopanningcell bindingepitopesinternalizationnanobodyparatopesphage displaysingle domain antibodyvariable heavy chain

Identifiers

PMID39381136
PMCPMC11456836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.